n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, BS; Gu, YC; Xie, C | 1 |
| Jin, Y; Li, H; Li, X; Yu, M; Zhang, H; Zhang, P | 1 |
1 review(s) available for n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide and Neoplasms
| Article | Year |
|---|---|
[Immune checkpoint inhibitors induced pituitary immune-related adverse events: diagnosis and management].
Topics: Antibodies, Monoclonal; CTLA-4 Antigen; Humans; Immune Checkpoint Inhibitors; Neoplasms; Programmed Cell Death 1 Receptor | 2022 |
1 other study(ies) available for n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide and Neoplasms
| Article | Year |
|---|---|
The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study.
Topics: China; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Neoplasms; United States | 2023 |